Literature DB >> 26076211

Addiction Treatment Within U.S. Correctional Facilities: Bridging the Gap Between Current Practice and Evidence-Based Care.

Sarah E Wakeman1, Josiah D Rich.   

Abstract

The United States leads the world in creating prisoners. This epidemic of incarceration is largely due to the "War on Drugs," which has resulted in criminalization of the disease of addiction. Half of prisoners have an active substance use disorder yet a minority receives formal treatment. Opioid agonist maintenance is among the most effective treatments for opioid use disorder. Maintenance treatment reduces illicit opioid use, crime, recidivism, and cost, yet few correctional facilities provide this lifesaving treatment. Increased access to opioid agonist maintenance as well as reexamination of drug policy is necessary to address this costly and morbid incarceration epidemic.

Keywords:  Incarceration; addiction; buprenorphine; jail; methadone; naltrexone; opioid; prison; substance use

Mesh:

Substances:

Year:  2015        PMID: 26076211     DOI: 10.1080/10550887.2015.1059217

Source DB:  PubMed          Journal:  J Addict Dis        ISSN: 1055-0887


  18 in total

1.  Expanding low-threshold buprenorphine to justice-involved individuals through mobile treatment: Addressing a critical care gap.

Authors:  Noa Krawczyk; Megan Buresh; Michael S Gordon; Thomas R Blue; Michael I Fingerhood; Deborah Agus
Journal:  J Subst Abuse Treat       Date:  2019-05-09

2.  Patterns of buprenorphine use and risk for re-arrest among highly vulnerable opioid-involved women released from jails in rural Appalachia.

Authors:  Hilary L Surratt; Michele Staton; Carl G Leukefeld; Carrie B Oser; J Matthew Webster
Journal:  J Addict Dis       Date:  2018-12-21

3.  Effectiveness of medication assisted treatment for opioid use in prison and jail settings: A meta-analysis and systematic review.

Authors:  Kelly E Moore; Walter Roberts; Holly H Reid; Kathryn M Z Smith; Lindsay M S Oberleitner; Sherry A McKee
Journal:  J Subst Abuse Treat       Date:  2018-12-15

4.  The impact of the opioid crisis on U.S. state prison systems.

Authors:  Christy K Scott; Michael L Dennis; Christine E Grella; Allison F Mischel; John Carnevale
Journal:  Health Justice       Date:  2021-07-24

5.  Utilization of opioid agonist therapy among incarcerated persons with opioid use disorder in Vancouver, Canada.

Authors:  Nikki Bozinoff; Kora DeBeck; M-J Milloy; Ekaterina Nosova; Nadia Fairbairn; Evan Wood; Kanna Hayashi
Journal:  Drug Alcohol Depend       Date:  2018-10-06       Impact factor: 4.492

6.  Very early disengagement and subsequent re-engagement in primary care Office Based Opioid Treatment (OBOT) with buprenorphine.

Authors:  David Hui; Zoe M Weinstein; Debbie M Cheng; Emily Quinn; Hyunjoong Kim; Colleen Labelle; Jeffrey H Samet
Journal:  J Subst Abuse Treat       Date:  2017-05-16

7.  Feasibility and Effectiveness of Continuing Methadone Maintenance Treatment During Incarceration Compared With Forced Withdrawal.

Authors:  Kelly E Moore; Lindsay Oberleitner; Kathryn M Z Smith; Kathleen Maurer; Sherry A McKee
Journal:  J Addict Med       Date:  2018 Mar/Apr       Impact factor: 3.702

Review 8.  Social vulnerabilities for substance use: Stressors, socially toxic environments, and discrimination and racism.

Authors:  Hortensia Amaro; Mariana Sanchez; Tara Bautista; Robynn Cox
Journal:  Neuropharmacology       Date:  2021-03-11       Impact factor: 5.250

9.  Linking criminal justice-involved individuals to HIV, Hepatitis C, and opioid use disorder prevention and treatment services upon release to the community: Progress, gaps, and future directions.

Authors:  Noor Taweh; Esther Schlossberg; Cynthia Frank; Ank Nijhawan; Irene Kuo; Kevin Knight; Sandra A Springer
Journal:  Int J Drug Policy       Date:  2021-05-18

10.  A clinical protocol of a comparative effectiveness trial of extended-release naltrexone versus extended-release buprenorphine with individuals leaving jail.

Authors:  Michael S Gordon; Shannon Gwin Mitchell; Thomas R Blue; Frank J Vocci; Marc J Fishman; Sean M Murphy; Kathy Couvillion; Kelly Maher; Danielle Ryan; Kevin Wenzel; Martha L Danner; Daniel K Jarvis
Journal:  J Subst Abuse Treat       Date:  2020-12-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.